Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Rocha de Paula, Mateus Rocha ^a   Gómez Ravetti, Martín ^b   Berretta, Regina ^a   Moscato, Pablo ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CELL PROTEIN; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; MACROPHAGE INFLAMMATORY PROTEIN 1DELTA; NEUROTROPHIN 3; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN BINDING PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN B;

ALZHEIMER DISEASE; ARTICLE; EARLY DIAGNOSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; PREDICTION; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; DATABASES, PROTEIN; EARLY DIAGNOSIS; HUMANS; SIGNAL TRANSDUCTION;

EID: 79953066206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017481     Document Type: Article

References (82)

1. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362.
2. Soares HD, Chen Y, Sabbagh M, Rohrer A, Schrijvers E, et al. (2009) Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels. Annals of the New York Academy of Sciences 1180: 56-67.
3. Gómez Ravetti M, Moscato P, (2008) Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS One 3: e3111.
4. Berretta R, Costa W, Moscato P, (2008) Combinatorial optimization models for finding genetic signatures from gene expression datasets. Methods Mol Biol 453: 363-377.
5. Hourani M, Berretta R, Mendes A, Moscato P, (2008) Genetic Signatures for a Rodent Model of Parkinson's Disease Using Combinatorial Optimization Methods. pp. 379-392 In: Bioinformatics, Humana Press.
6. Walker JM, Mendes A, Scott RJ, Moscato P, (2008) Microarrays-identifying molecular portraits for prostate tumors with different gleason patterns. In: Trent RJ, editors. pp. 131-151 Clinical Bioinformatics, Humana Press, volume 141 of Methods in Molecular Medicine.
7. Rosso OA, Mendes A, Berretta R, Rostas JA, Hunter M, et al. (2009) Distinguishing childhood absence epilepsy patients from controls by the analysis of their background brain electrical activity (II): a combinatorial optimization approach for electrode selection. J Neurosci Methods 181: 257-267.
8. Gómez Ravetti M, Berretta R, Moscato P, (2009) Novel Biomarkers for Prostate Cancer Revealed by (α,β)-k-Feature Sets. pp. 149-175 In: Foundations of Computational Intelligence Volume 5, Springer Berlin/ Heidelberg, volume 5, chapter 7.
9. Cotta C, Moscato P, (2003) The k-Feature Set Problem is W[2]-complete. Journal of Computer and System Sciences 67: 686-690.
10. Cotta C, Sloper C, Moscato P, (2004) Evolutionary Search of Thresholds for Robust Feature Set Selection: Application to the Analysis of Microarray Data. In: Raidl GR, Cagnoni S, Branke J, Corne DW, Drechsler R, editors. pp. 21-30 Applications of Evolutionary Computing, Springer Berlin/Heidelberg, Lecture Notes in Computer Science.
11. Berretta R, Mendes A, Moscato P, (2007) Selection of Discriminative Genes in Microarray Experiments Using Mathematical Programming. Journal of Research and Practice in Information Technology 39: 287-299.
12. Cotta C, Langston MA, Moscato P, (2007) Combinatorial and Algorithmic Issues for Microarray Analysis. pp. 74.1-74.14 In: Handbook of Approximation Algorithms and Metaheuristics, Chapman & Hall/CRC.
13. Witten IH, Frank E, (2005) Data Mining: Practical machine learning tools and techniques Morgan Kaufmann, 2nd edition.
14. Moscato P, Mathieson L, Mendes A, Berretta R, (2005) The electronic primaries: predicting the U.S. presidency using feature selection with safe data reduction. ACSC '05: Proceedings of the Twenty-eighth Australasian conference on Computer Science Darlinghurst, Australia, Australia Australian Computer Society, Inc pp. 371-379.
15. Moscato P, Mendes A, Berretta R, (2007) Benchmarking a memetic algorithm for ordering microarray data. Biosystems 88: 56-75.
16. Gómez Ravetti M, Rosso OA, Berretta R, Moscato P, (2010) Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease. PloS one 5: e10153.
17. Fayyad UM, Irani KB, (1993) Multi-Interval Discretization of Continuous-Valued Attributes for Classification Learning. 13th International Joint Conference on Artificial Intelligence. Morgan Kaufmann.
18. Bauer E, Kohavi R, (1999) An Empirical Comparison of Voting Classification Algorithms: Bagging, Boosting, and Variants. Mach Learn 36: 105-139.
19. Tibshirani R, Hastie T, Narasimhan B, Chu G, (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proceedings of the National Academy of Sciences of the United states of America 99: 6567-6572.
20. Vezhnevets A, Barinova O, (2007) Avoiding boosting overfitting by removing confusing samples. Machine Learning: ECML 2007 4701/2007 pp. 430-441.
21. Angelova A, Abu-Mostafa Y, Perona P, (2005) Pruning training sets for learning of object categories. pp. 494-501 In: Proceedings of the 2005 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (CVPR'05). IEEE Computer Society, volume 1.
22. Ahmed A, Fujisawa T, Niu XL, Ahmad S, Al-Ani B, et al. (2009) Angiopoietin-2 confers atheroprotection in apoE-/-mice by inhibiting LDL oxidation via nitric oxide. Circulation research pp. 1333-1336.
23. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P, (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. Journal of Alzheimer's Disease 10: 111-118.
24. Fialaa M, Lina J, Ringmanb J, Kermani-Arabc V, Tsaoa G, et al. (2005) Ineffective phagocytosis of amyloid-{ß} by macrophages of Alzheimer's disease patients. Journal of Alzheimer's Disease 7: 221-232.
25. Iarlori C, Gambi D, Gambi F, Lucci I, Feliciani C, et al. (2005) Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Experimental gerontology 40: 605-611.
26. Tripathy D, Thirumangalakudi L, Grammas P, (2010) RANTES upregulation in the Alzheimer's disease brain: A possible neuroprotective role. Neurobiology of Aging 31: 8-16.
27. Reale M, Iarlori C, Feliciani C, Gambi D, (2008) Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. Journal of Alzheimer's Disease 14: 147-159.
28. Richartz E, Noda S, Schott K, Günthner A, Lewczuk P, et al. (2000) Increased serum levels of CD95 in Alzheimer's disease. Dementia and geriatric cognitive disorders 13: 178-182.
29. Frey C, Bonert A, Kratzsch T, Rexroth G, Rösch W, et al. (2006) Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease. Journal of Neural Transmission 113: 1753-1761.
30. Lombardi VR, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R, (2004) Association between APOE epsilon4 allele and increased expression of CD95 on T cells from patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol 26: 523-529.
31. Yew DT, Li P, Others, (2004) Fas and activated caspase 8 in normal, Alzheimer and multiple infarct brains. Neuroscience letters 367: 113-117.
32. Su JH, Anderson AJ, Cribbs DH, Tu C, Tong L, et al. (2003) Fas and Fas Ligand are associated with neuritic degeneration in the AD brain and participate in [beta]-amyloid-induced neuronal death. Neurobiology of disease 12: 182-193.
33. de la Monte SM, Chiche JD, von dem Bussche A, Sanyal S, Lahousse SA, et al. (2003) Nitric oxide synthase-3 overexpression causes apoptosis and impairs neuronal mitochondrial function: relevance to Alzheimer's-type neurodegeneration. Laboratory investigation 83: 287-298.
34. Feuk L, Prince J, Breen G, Emahazion T, Carothers A, et al. (2000) Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Human genetics 107: 391-396.
35. Nishimura T, Akiyama H, Yonehara S, Kondo H, Ikeda K, et al. (1995) Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain research 695: 137-145.
36. Tarkowski E, Blennow K, Wallin A, Tarkowski A, (1999) Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent. Alzheimer disease and vascular dementia J Clin Immunol 19: 223-230.
37. de La Monte SM, Wands JR, (2001) Alzheimer-associated neuronal thread protein-induced apoptosis and impaired mitochondrial function in human central nervous system-derived neuronal cells. Journal of Neuropathology & Experimental Neurology 60: 195-207.
38. Andreoli V, Nicoletti G, Romeo N, Condino F, La Russa A, et al. (2007) Fas antigen and sporadic Alzheimer's disease in Southern Italy: evaluation of two polymorphisms in the TNFRSF6 gene. Neurochemical Research 32: 1445-1449.
39. He X, Zhang Z, Zhang J, Zhou Y, Tang M, et al. (2006) The Fas gene A-670G polymorphism is not associated with sporadic Alzheimer disease in a Chinese Han population. Brain research 1082: 192-195.
40. Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, et al. (2000) The Fas Promoter Polymorphism at Position-670 Is Not Associated with Late-Onset Sporadic Alzheimer's Disease. Dementia and geriatric cognitive disorders 17: 143-146.
41. Feuk L, Prince JA, Blennow K, Brookes AJ, (2002) Further evidence for role of a promoter variant in the TNFRSF6 gene in Alzheimer disease. Human mutation 21: 53-60.
42. Chiappelli M, Nasi M, Cossarizza A, Porcellini E, Tumini E, et al. (2006) Polymorphisms of Fas Gene: Relationship with Alzheimer's Disease and Cognitive Decline. Dementia and geriatric cognitive disorders 22: 296-300.
43. Festa E, Hankiewicz K, Kim S, Skurnick J, Wolansky L, et al. (2009) Serum levels of CXCL13 are elevated in active multiple sclerosis. Multiple Sclerosis 15: 1271-1279.
44. Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van Evercooren A, et al. (2010) IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells. Journal of Neuroimmunology 223: 131-134.
45. Riemer C, Queck I, Simon D, Kurth R, Baier M, (2000) Identification of upregulated genes in scrapie-infected brain tissue. Journal of Virology 74: 10245-10248.
46. Baker C, Martin D, Manuelidis L, (2002) Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles. Journal of virology 76: 10905-10913.
47. Arenas E, Persson H, (1994) Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature pp. 368-371.
48. Hock C, Heese K, Müller-Spahn F, Huber P, Riesen W, et al. (2000) Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Molecular psychiatry 5: 510-513.
49. Durany N, Michel T, Kurt J, Cruz-Sánchez FF, Cervós-Navarro J, et al. (2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. International Journal of Developmental Neuroscience 18: 807-813.
50. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H, (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7: 2925-2928.
51. Saragovi HU, Hamel E, Di Polo A, (2009) A Neurotrophic Rationale for the Therapy of Neurodegenerative Disorders. Current Alzheimer Research 6: 419-423.
52. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, et al. (2009) [beta]-amyloid impairs axonal bdnf retrograde trafficking. Neurobiology of Aging In Press, Corrected Proof:-.
53. Knowles JK, Rajadas J, Nguyen TVV, Yang T, LeMieux MC, et al. (2009) The p75 Neurotrophin Receptor Promotes Amyloid-{beta}(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo. Journal of Neuroscience 29: 10627-10637.
54. Schulte-Herbrüggen O, Jockers-Scherübl MC, Hellweg R, (2008) Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Current Alzheimer research 5: 38-44.
55. Longo FM, Yang T, Knowles JK, Xie Y, Moore LA, et al. (2007) Small Molecule Neurotrophin Receptor Ligands: Novel Strategies for Targeting Alzheimers Disease Mechanisms. Current Alzheimer Research 4: 503-506.
56. Cole GM, Frautschy SA, (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Experimental gerontology 42: 10-21.
57. Fombonne J, Rabizadeh S, Banwait S, Mehlen P, Bredesen DE, (2009) Selective vulnerability in Alzheimer's disease: Amyloid precursor protein and p75NTR interaction. Annals of neurology 65: 294-303.
58. Masoudi R, Ioannou MS, Coughlin MD, Pagadala P, Neet KE, et al. (2009) Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. Journal of Biological Chemistry 284: 18424.
59. Diarra A, Geetha T, Potter P, Babu JR, (2009) Signaling of the neurotrophin receptor p75 in relation to Alzheimer's disease. Biochemical and biophysical research communications 390: 352-356.
60. Coulson EJ, May LM, Sykes AM, Hamlin AS, (2009) The Role of the p75 Neurotrophin Receptor in Cholinergic Dysfunction in Alzheimer's Disease. The Neuroscientist 15: 317-323.
61. Bengoechea TG, Chen Z, O'Leary D, Masliah E, Lee KF, (2009) p75 reduces β-amyloid-induced sympathetic innervation deficits in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences 106: 7870-7875.
62. Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, et al. (2008) Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 28: 3941-3946.
63. Coulson EJ, (2006) Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J Neurochem 98: 654-660.
64. Chiarini A, Dal Pra I, Whitfield JF, Armato U, (2006) The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Italian journal of anatomy and embryology 111: 221-246.
65. Mirnics ZK, Yan C, Portugal C, Kim TW, Saragovi HU, et al. (2005) P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of disease 20: 969-985.
66. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, et al. (1997) Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. Journal of Clinical Investigation 100: 2333-2340.
67. Wolf SA, Kronenberg G, Lehmann K, Blankenship A, Overall R, et al. (2006) Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biological psychiatry 60: 1314-1323.
68. Hock C, Heese K, Hulette C, Rosenberg C, Otten U, (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Archives of neurology 57: 846-851.
69. Lesne S, Gabriel C, Nelson DA, White E, MacKenzie ET, et al. (2005) Akt-dependent expression of NAIP-1 protects neurons against amyloid-β toxicity. Journal of Biological Chemistry 280: 24941-24947.
70. Xiyang YB, Liu S, Liu J, Hao CG, Wang ZJ, et al. (2009) Roles of Platelet-Derived Growth Factor-B Expression in the Ventral Horn and Motor Cortex in the Spinal Cord-Hemisected Rhesus Monkey. Journal of neurotrauma 26: 275-287.
71. Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, et al. (2008) Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. Journal of Neuroscience 28: 10451-10459.
72. Falk T, Zhang S, Sherman SJ, (2009) Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Molecular Neurodegeneration 1: 49.
73. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, et al. (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature pp. 917-921.
74. Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, et al. (2009) Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience 163: 55-72.
75. Manczak M, Mao P, Nakamura K, Bebbington C, Park B, et al. (2009) Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Human molecular genetics 18: 3876-3893.
76. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, et al. (2009) A [beta]-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiology of disease 34: 63-70.
77. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, et al. (2010) Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease. Rejuvenation Research pp. 541-546.
78. Murphy GM Jr, Yang L, Cordell B, (1998) Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J Biol Chem 273: 20967-20971.
79. Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, et al. (1993) Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. Journal of Neural Transmission: Parkinson's Disease and Dementia Section 5: 165-176.
80. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, et al. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31: 224-243.
81. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, et al. (2010) A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease. Archives of Neurology 67: 1077-1081.
82. Chen-Plotkin A, Hu W, Siderowf A, Weintraub D, Goldmann Gross R, et al. (2009) Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology.